Characteristics and outcome determinants in children, adolescents and young adults who failed tisagenlecleucel for B-cell acute lymphoblastic leukemia

Leukemia

Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT

Blood

Buechner J, Poetschger U, Bader P, Yeşilipek MA, Pichler H, Palma J, Staciuk R, Riha P, Kriván G, Ifversen M, Güngör T, Goussetis E, Kalwak K, Toporski J, Gabriel M, Renard MM, Diaz-de-Heredia C, Matic T, Calkoen FG, Svec P, Meisel R, Balduzzi AC, Locatelli F, Peters C, Dalle JH, Stein J

doi: 10.1182/blood.2025030951

Leukemia

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study

Am J Hematol

Pasvolsky O, Shimony S, Saliba RM, Marcoux C, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin JH, Koreth J, Cutler CS, Paolino JD, Duncan CN, Lehmann LE, DeAngelo DJ, Jain N, Champlin R, Shpall E, Luskin MR, Kebriaei P

doi: 10.1002/ajh.70101

Leukemia

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation

Leuk Lymphoma

Claiborne JP, Tsai HL, Ghiaur G, Smith BD, Gojo I, DeZern AE, Ambinder AJ, Jain T, Prince GT, Gondek LP, Karantanos T, Dalton WB, Levis MJ, Webster JA

doi: 10.1080/10428194.2026.2628206

Leukemia

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Leukemia

Shah BD, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Tzachanis D, Arellano ML, Lin Y, Baer MR, Schiller GJ, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Mao D, Adhikary S, Zhou L, Hadjivassileva T, Damico Khalid R, Ghobadi A, Oluwole OO

doi: 10.1038/s41375-025-02532-7

Leukemia

Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen

Leuk Lymphoma

Amiri D, Mirzaei M, Bahri T, Barkhordar M, Nejati N, Babakhani D, Biglari M, Yaghmaie M, Rad S, Vaezi M, Alimoghadam K, Janbabai G, Mousavi SA, Fumani HK, Shirjani ST, Ghavamzadeh A

doi: 10.1080/10428194.2025.2548968

Leukemia

Similar Outcome With Haploidentical, Matched Sibling, or Matched Unrelated Donor Hematopoietic Cell Transplantation for Adult Patients With Adverse-Risk TP53-Mutated Acute Myeloid Leukemia in First Remission: A Comparative Study From the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Am J Hematol

Ru Y, Chen J, Ferhat AT, Labussière-Wallet H, Gedde-Dahl T, Kröger N, Socié G, Yakoub-Agha I, Eder M, Mielke S, Wu D, Mohty M, Ciceri F, Gorin NC

doi: 10.1002/ajh.70069

Leukemia

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Haematologica

Balduzzi A, Glogova E, Peters C, Sedlacek P, Dalle JH, Locatelli F, Meisel R, Burkhardt B, Buechner J, Wachowiak J, Bierings M, Staciuk R, Graphakos S, Güngör T, Yesilipek A, Svec P, Palma J, Krivan G, Diaz-de-Heredia C, Limido F, Ansari M, Kalwak K, Bader P, Ifversen M

doi: 10.3324/haematol.2025.287456

Leukemia

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Leukemia

Cusan M, Larkin K, Nicolet D, Jurinovic V, Mrózek K, Batcha AMN, Rothenberg-Thurley M, Schneider S, Sauerland C, Görlich D, Krug U, Berdel WE, Woermann BJ, Hiddemann W, Braess J, Spiekermann K, Greif PA, Blachly JS, Mims AS, Walker CJ, Walker MC, Oakes CC, Orwick S, Carroll AJ, Blum WG, Powell BL, Kolitz JE, Moore JO, Mayer RJ, Larson RA, Stone RM, Byrd JC, Metzeler KH, Herold T, Eisfeld AK

doi: 10.1038/s41375-025-02644-0

Leukemia

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults

Blood Cancer J

Harris EJ, Karaoglu DA, Sukhanova M, Abaza Y, Karantanos T, Eisfeld AK, Anderson C, Lin C, Moreno Vanegas YA, Badar T, Coltoff A, Knepper TC, Ozkaya N, Youshanlouei HR, Cetin S, Patel AA, DuVall AS, Drazer MW, Wang P, Tjota M, Segal JP, Venkataraman G, Gurbuxani S, Cheng JX, Arber DA, Larson RA, Odenike O, Webster J, Shah B, Stock W, Saygin C

doi: 10.1038/s41408-025-01350-5

Related content

Outcome of children with B-cell acute lymphoblastic leukemia with hypodiploidy or BCR::ABL1 fusion undergoing allogeneic HSCT

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia-A Retrospective, Dual-Center Study

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3

Outcome of allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia patients who underwent myeloablative TBI-free conditioning regimen

Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM Trial

Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)

Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults